Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fentanyl
Drug ID BADD_D00879
Description Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia.[A179542] Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and [oxycodone]. Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin.[A179542] In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths).[L6748] Opioid overdoses kill an average of 11 Canadians daily.[L6751] Fentanyl was FDA approved in 1968.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613]
Indications and Usage Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia.[Label] These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia.[Label] Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.[Label] Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.[L6598,L6601,L6604,L6607,L922,L6610]
Marketing Status approved; illicit; investigational; vet_approved
ATC Code N01AH01; N02AB03
DrugBank ID DB00813
KEGG ID D00320
MeSH ID D005283
PubChem ID 3345
TTD Drug ID D0E1WI
NDC Product Code 59116-2642; 55700-753; 60505-7008; 60505-7016; 60505-7017; 59116-2645; 60505-7015; 60505-7083; 63629-4813; 47781-427; 63459-541; 63629-4976; 0378-9126; 60505-7010; 60505-7080; 59116-2643; 47781-424; 60505-7006; 60505-7087; 63459-544; 63459-548; 0378-9125; 59116-2641; 64181-0008; 47781-423; 60505-7012; 60505-7013; 60505-7082; 63459-546; 0378-9121; 0378-9127; 60505-7011; 0378-9119; 0378-9122; 55700-973; 60505-7086; 63629-4974; 59116-2646; 55700-597; 60505-7014; 60505-7085; 0378-9123; 59116-2640; 47781-426; 47781-428; 55700-772; 60505-7007; 60505-7009; 60505-7081; 60505-7084; 63459-542; 0378-9124; 59116-2644; 55700-748; 55700-749; 55700-972
UNII UF599785JZ
Synonyms Fentanyl | Phentanyl | Fentanest | Fentanyl Citrate | R-4263 | R 4263 | R4263 | Sublimaze | Transmucosal Oral Fentanyl Citrate | Duragesic | Durogesic | Fentora
Chemical Information
Molecular Formula C22H28N2O
CAS Registry Number 437-38-7
SMILES CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sleep disorder19.02.04.001--Not Available
Sluggishness08.01.01.004--Not Available
Sneezing22.12.03.024--
Snoring22.12.03.0250.000423%Not Available
Somnolence19.02.05.003; 17.02.04.0060.013765%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Spinal compression fracture15.08.05.004; 14.04.04.003; 12.04.04.001--Not Available
Sputum increased22.02.03.007--Not Available
Stevens-Johnson syndrome23.03.01.007; 10.01.01.045; 12.03.01.014; 11.07.01.005--
Stomatitis07.05.06.005--
Stupor19.02.05.004; 17.02.04.007--Not Available
Subdural haematoma24.07.04.005; 17.08.05.002; 12.01.10.003--Not Available
Swelling08.01.03.015--Not Available
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.018--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Synovitis15.04.02.001--Not Available
Tachycardia02.03.02.007--Not Available
Tendon disorder12.01.07.019; 15.07.01.002--Not Available
Tension19.06.02.005--Not Available
Therapeutic response decreased08.06.01.016--Not Available
Therapeutic response increased08.06.01.021--Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Throat tightness22.12.03.031; 19.01.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue blistering07.14.02.014--Not Available
Tongue disorder07.14.01.002--Not Available
The 15th Page    First    Pre   15 16 17 18 19    Next   Last    Total 22 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene